Platelet Lysate Wound Dressing for Sustained Healing and Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound care technologies for severe wounds, such as those caused by improvised explosive devices and diabetic foot ulcers, are inefficient in accelerating healing, costly, and pose safety concerns, with limited efficacy in reducing infection and amputation risks.
Innovation Solution
Dressings comprising human platelet lysate (hPL) with a delivery vehicle, optionally including antimicrobial and hemostatic agents, provide sustained delivery of growth factors and therapeutic agents to promote wound healing, hemostasis, and infection control, suitable for both acute and chronic wounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard wound care treatments are used for diabetic foot ulcers, then basic wound coverage is provided, but healing rates remain low (25% after 12 weeks) and infection risk persists
Solution Approach 1:
The patent combines multiple therapeutic functions into a single dressing system: hPL for growth factor delivery, antimicrobial agents for infection control, and hemostatic agents for blood loss management. This integrated approach simultaneously addresses healing rate and infection control rather than treating them separately
Solution Approach 2:
The patent changes the chemical and biological parameters of the wound environment by delivering concentrated growth factors (PDGF, TGF-beta, VEGF) from hPL, altering the wound's healing trajectory from chronic non-healing to active regeneration, thereby improving both healing rate and infection resistance
2Productivity
If advanced wound care technologies are used, then healing acceleration is achieved, but costs increase significantly and safety concerns arise
Solution Approach 1:
The patent employs a disposable dressing system containing hPL that is applied topically and then discarded after use. This avoids the need for expensive, complex devices requiring manufacturing, sterilization, and quality control, while still delivering effective growth factor therapy at lower cost
Solution Approach 2:
The patent extracts and concentrates the beneficial growth factors from platelets into hPL, isolating the therapeutic components from the whole blood system. This allows delivery of healing-accelerating factors without the safety concerns associated with cellular components or complex biologics
3Duration of action of moving object
If platelet lysate is applied to wounds, then growth factor delivery is sustained, but dressing complexity increases
Solution Approach 1:
The patent uses composite dressing materials that integrate hPL with absorbent matrices and delivery vehicles. These composites provide sustained growth factor release while maintaining simple application procedures, balancing extended duration of action with ease of use
Data Source
AI summary
A dressing comprises a delivery vehicle and platelet lysate. The dressing can also include an antimicrobial agent, a hemostatic agent, and a binder. It is contemplated that the dressing can be used for expediting hemostasis, improving antimicrobial activity, minimizing fluid loss, and accelerating wound healing when applied to a wound. The dressing would be useful in applications including military in-theater medical care and for conditions such as diabetic foot ulcers, as well as other applications.